[{"id":"e3b4bad8-8656-47cc-998e-a5d2146657b6","acronym":"ALCHEMIST Screening","url":"https://clinicaltrials.gov/study/NCT02194738","created_at":"2021-01-18T10:15:39.910Z","updated_at":"2025-02-25T12:26:10.714Z","phase":"","brief_title":"Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)","source_id_and_acronym":"NCT02194738 - ALCHEMIST Screening","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • ALK • PIK3CA • PTEN • PD-1 • CTLA4","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement","tags":["EGFR • PD-L1 • ALK • PIK3CA • PTEN • PD-1 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Lynparza (olaparib) • cisplatin • Xalkori (crizotinib) • erlotinib • carboplatin • gemcitabine • paclitaxel • docetaxel • Mektovi (binimetinib) • pemetrexed • sapanisertib (CB-228) • Zaltrap (ziv-aflibercept IV) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • Pembroria (pembrolizumab biosimilar) • Pemfexy (pemetrexed) • liposomal gemcitabine (FF-10832)"],"overall_status":"Recruiting","enrollment":" Enrollment 8300","initiation":"Initiation: 09/26/2014","start_date":" 09/26/2014","primary_txt":" Primary completion: 09/28/2026","primary_completion_date":" 09/28/2026","study_txt":" Completion: 09/28/2026","study_completion_date":" 09/28/2026","last_update_posted":"2025-02-24"},{"id":"94c5e31a-2356-49e3-9f8b-a6c9b2c0747c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02298959","created_at":"2023-12-06T16:15:23.236Z","updated_at":"2024-07-02T16:34:58.835Z","phase":"Phase 1","brief_title":"Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer","source_id_and_acronym":"NCT02298959","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • HGF • CTAG1B • CD4 • FGF • MLANA","pipe":"","alterations":" ","tags":["CD8 • HGF • CTAG1B • CD4 • FGF • MLANA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Zaltrap (ziv-aflibercept IV)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 04/08/2015","start_date":" 04/08/2015","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-05"},{"id":"c765d8e3-ee9e-434f-8e92-e8b28b2e7411","acronym":"","url":"https://clinicaltrials.gov/study/NCT00407654","created_at":"2021-01-18T01:25:40.828Z","updated_at":"2024-07-02T16:35:16.566Z","phase":"Phase 2","brief_title":"VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer","source_id_and_acronym":"NCT00407654","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zaltrap (ziv-aflibercept IV)"],"overall_status":"Completed","enrollment":" Enrollment 75","initiation":"Initiation: 10/01/2006","start_date":" 10/01/2006","primary_txt":" Primary completion: 09/01/2012","primary_completion_date":" 09/01/2012","study_txt":" Completion: 09/01/2012","study_completion_date":" 09/01/2012","last_update_posted":"2024-03-04"},{"id":"cd0237de-83fb-4067-a3c9-ebaeb1c9ea4c","acronym":"","url":"https://clinicaltrials.gov/study/NCT06047379","created_at":"2023-09-21T14:10:36.425Z","updated_at":"2024-07-02T16:35:19.429Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","source_id_and_acronym":"NCT06047379","lead_sponsor":"Neonc Technologies, Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" IDH wild-type","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Yervoy (ipilimumab) • carboplatin • paclitaxel • 5-fluorouracil • Stivarga (regorafenib) • oxaliplatin • irinotecan • leucovorin calcium • Vegzelma (bevacizumab-adcd) • Zaltrap (ziv-aflibercept IV)"],"overall_status":"Recruiting","enrollment":" Enrollment 134","initiation":"Initiation: 11/01/2023","start_date":" 11/01/2023","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2024-02-14"},{"id":"369a58dd-4a69-448b-9669-35759434dc53","acronym":"TWICE-IRI","url":"https://clinicaltrials.gov/study/NCT04392479","created_at":"2021-01-18T21:11:59.050Z","updated_at":"2024-07-02T16:35:32.165Z","phase":"Phase 3","brief_title":"TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study.","source_id_and_acronym":"NCT04392479 - TWICE-IRI","lead_sponsor":"GCS IHFB Cognacq-Jay","biomarkers":" KDR • FLT4 • VEGFC","pipe":"","alterations":" ","tags":["KDR • FLT4 • VEGFC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • irinotecan • leucovorin calcium • Zaltrap (ziv-aflibercept IV)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 202","initiation":"Initiation: 09/02/2020","start_date":" 09/02/2020","primary_txt":" Primary completion: 06/15/2023","primary_completion_date":" 06/15/2023","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2023-10-23"},{"id":"2ed109f9-55eb-4a68-a91f-9e24415e3b0f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01782443","created_at":"2022-11-09T19:56:50.419Z","updated_at":"2024-07-02T16:35:40.179Z","phase":"Phase 2","brief_title":"Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors","source_id_and_acronym":"NCT01782443","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" CHGA","pipe":"","alterations":" ","tags":["CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zaltrap (ziv-aflibercept IV)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 02/13/2013","start_date":" 02/13/2013","primary_txt":" Primary completion: 03/01/2021","primary_completion_date":" 03/01/2021","study_txt":" Completion: 12/26/2021","study_completion_date":" 12/26/2021","last_update_posted":"2023-08-14"},{"id":"f1d4236e-f4b2-4600-82e7-b8536383bf33","acronym":"SAMCO","url":"https://clinicaltrials.gov/study/NCT03186326","created_at":"2021-01-18T15:42:42.125Z","updated_at":"2024-07-02T16:36:05.186Z","phase":"Phase 2","brief_title":"Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer","source_id_and_acronym":"NCT03186326 - SAMCO","lead_sponsor":"Federation Francophone de Cancerologie Digestive","biomarkers":" BRAF • MSI • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" MSI-H/dMMR • BRAF mutation • RAS mutation • MSH6 expression","tags":["BRAF • MSI • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • BRAF mutation • RAS mutation • MSH6 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • Vectibix (panitumumab) • Bavencio (avelumab) • oxaliplatin • irinotecan • leucovorin calcium • Zaltrap (ziv-aflibercept IV)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 132","initiation":"Initiation: 04/24/2018","start_date":" 04/24/2018","primary_txt":" Primary completion: 05/31/2022","primary_completion_date":" 05/31/2022","study_txt":" Completion: 05/31/2023","study_completion_date":" 05/31/2023","last_update_posted":"2022-08-19"},{"id":"31a315ca-0665-4fb8-b8a9-bc26bbb5b17c","acronym":"FOLFA","url":"https://clinicaltrials.gov/study/NCT02384759","created_at":"2021-01-18T11:21:59.164Z","updated_at":"2024-07-02T16:36:14.164Z","phase":"Phase 2","brief_title":"Aflibercept +/- LV5FU2 in First Line of Non-resectalbe Metastatic Colorectal Cancers","source_id_and_acronym":"NCT02384759 - FOLFA","lead_sponsor":"Federation Francophone de Cancerologie Digestive","biomarkers":" TYMS","pipe":"","alterations":" ","tags":["TYMS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zaltrap (ziv-aflibercept IV)"],"overall_status":"Completed","enrollment":" Enrollment 117","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 06/01/2021","primary_completion_date":" 06/01/2021","study_txt":" Completion: 06/01/2021","study_completion_date":" 06/01/2021","last_update_posted":"2022-04-04"},{"id":"d6d64b89-f7f7-4bec-a903-6fffbe1ea5b6","acronym":"DISTINCTIVE","url":"https://clinicaltrials.gov/study/NCT04252456","created_at":"2021-01-18T20:39:55.170Z","updated_at":"2024-07-02T16:36:50.523Z","phase":"","brief_title":"Folfiri/aflIbercept in Metastatic coloreCTal Cancer patIents With RAS Validated Wild typE Status","source_id_and_acronym":"NCT04252456 - DISTINCTIVE","lead_sponsor":"Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente","biomarkers":" KDR • RAS • FLT4 • IL1A","pipe":" | ","alterations":" RAS wild-type","tags":["KDR • RAS • FLT4 • IL1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • irinotecan • leucovorin calcium • Zaltrap (ziv-aflibercept IV)"],"overall_status":"Unknown status","enrollment":" Enrollment 150","initiation":"Initiation: 04/23/2018","start_date":" 04/23/2018","primary_txt":" Primary completion: 04/01/2020","primary_completion_date":" 04/01/2020","study_txt":" Completion: 02/01/2021","study_completion_date":" 02/01/2021","last_update_posted":"2020-02-05"},{"id":"5881532e-c856-4fdf-b007-62afa39b90eb","acronym":"PERMAD","url":"https://clinicaltrials.gov/study/NCT02331927","created_at":"2021-01-18T11:04:13.685Z","updated_at":"2024-07-02T16:36:55.376Z","phase":"Phase 2","brief_title":"PERMAD: Personalized Marker-driven Early Switch to Aflibercept in Patients With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT02331927 - PERMAD","lead_sponsor":"University of Ulm","biomarkers":" VEGFB","pipe":"","alterations":" ","tags":["VEGFB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • oxaliplatin • irinotecan • Zaltrap (ziv-aflibercept IV)"],"overall_status":"Unknown status","enrollment":" Enrollment 150","initiation":"Initiation: 03/01/2015","start_date":" 03/01/2015","primary_txt":" Primary completion: 03/01/2020","primary_completion_date":" 03/01/2020","study_txt":" Completion: 03/01/2021","study_completion_date":" 03/01/2021","last_update_posted":"2019-09-20"},{"id":"7a7e05b0-0f85-4f52-a5af-9804319f36a6","acronym":"X-TRAP","url":"https://clinicaltrials.gov/study/NCT01661972","created_at":"2021-01-18T07:10:45.854Z","updated_at":"2024-07-02T16:37:05.773Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer","source_id_and_acronym":"NCT01661972 - X-TRAP","lead_sponsor":"John Strickler, M.D.","biomarkers":" EGFR • KRAS","pipe":" | ","alterations":" RAS wild-type","tags":["EGFR • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • Zaltrap (ziv-aflibercept IV)"],"overall_status":"Completed","enrollment":" Enrollment 63","initiation":"Initiation: 08/01/2012","start_date":" 08/01/2012","primary_txt":" Primary completion: 06/12/2016","primary_completion_date":" 06/12/2016","study_txt":" Completion: 06/12/2016","study_completion_date":" 06/12/2016","last_update_posted":"2018-10-29"},{"id":"b90c7697-6311-4262-9536-bc47534419d3","acronym":"AMALTHEA","url":"https://clinicaltrials.gov/study/NCT02129257","created_at":"2021-01-18T09:52:23.572Z","updated_at":"2024-07-02T16:37:16.932Z","phase":"Phase 2","brief_title":"Clinical Trial of Combination Chemotherapy With Aflibercept in Patients With Advanced Colorectal Cancer","source_id_and_acronym":"NCT02129257 - AMALTHEA","lead_sponsor":"Hellenic Cooperative Oncology Group","biomarkers":" KDR • HGF • HIF1A • FLT1 • VEGFB • VEGFC • FGF • NRP1","pipe":"","alterations":" ","tags":["KDR • HGF • HIF1A • FLT1 • VEGFB • VEGFC • FGF • NRP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • irinotecan • leucovorin calcium • Zaltrap (ziv-aflibercept IV)"],"overall_status":"Completed","enrollment":" Enrollment 73","initiation":"Initiation: 05/26/2014","start_date":" 05/26/2014","primary_txt":" Primary completion: 01/01/2017","primary_completion_date":" 01/01/2017","study_txt":" Completion: 09/25/2017","study_completion_date":" 09/25/2017","last_update_posted":"2017-10-24"},{"id":"921f4870-fe54-40a0-bdb1-8d3e44615ac9","acronym":"","url":"https://clinicaltrials.gov/study/NCT00357760","created_at":"2021-01-18T01:14:25.918Z","updated_at":"2024-07-02T16:37:20.715Z","phase":"Phase 2","brief_title":"Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer","source_id_and_acronym":"NCT00357760","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" VEGFA • IL2","pipe":"","alterations":" ","tags":["VEGFA • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zaltrap (ziv-aflibercept IV)"],"overall_status":"Completed","enrollment":" Enrollment 94","initiation":"Initiation: 12/01/2007","start_date":" 12/01/2007","primary_txt":" Primary completion: 10/01/2015","primary_completion_date":" 10/01/2015","study_txt":" Completion: 10/01/2015","study_completion_date":" 10/01/2015","last_update_posted":"2017-06-23"},{"id":"334ab055-453f-4174-8daa-5aee1828dedf","acronym":"","url":"https://clinicaltrials.gov/study/NCT00729157","created_at":"2021-01-18T02:44:44.789Z","updated_at":"2024-07-02T16:37:24.391Z","phase":"Phase 2","brief_title":"Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy","source_id_and_acronym":"NCT00729157","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TG","pipe":"","alterations":" ","tags":["TG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zaltrap (ziv-aflibercept IV)"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 08/01/2008","start_date":" 08/01/2008","primary_txt":" Primary completion: 10/01/2012","primary_completion_date":" 10/01/2012","study_txt":" Completion: 11/01/2012","study_completion_date":" 11/01/2012","last_update_posted":"2017-03-15"},{"id":"8a217d20-9396-45ac-8136-8d17905382bf","acronym":"","url":"https://clinicaltrials.gov/study/NCT00327171","created_at":"2023-10-15T04:12:21.103Z","updated_at":"2024-07-02T16:37:31.478Z","phase":"Phase 2","brief_title":"Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer","source_id_and_acronym":"NCT00327171","lead_sponsor":"Sanofi","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e topotecan • Zaltrap (ziv-aflibercept IV)"],"overall_status":"Completed","enrollment":" Enrollment 218","initiation":"Initiation: 05/01/2006","start_date":" 05/01/2006","primary_txt":" Primary completion: 04/01/2008","primary_completion_date":" 04/01/2008","study_txt":" Completion: 03/01/2010","study_completion_date":" 03/01/2010","last_update_posted":"2016-06-07"}]